

Painful ulcer on the dorsum of the hand

Úlcera dolorosa no dorso da mão

Flávia R. Ferreira^{1*}, Fátima M. O. Rabay¹, Luisa R. Ayoub^{1,2}, Caroline A. Gonçalves¹,
Guilherme P. da Silva¹, Julia L. F. Bolsoni¹, and Mariana F. da Silva³

¹Dermatology Service, Hospital Municipal Universitário de Taubaté, Universidade de Taubaté (H.MUT/ UNITAU), Taubaté; ²Dermatology Service, Hospital do Servidor Público Municipal de São Paulo (HSPM); ³Department of Medicine, HUMANITAS, Faculdade de Ciências Médicas em São José dos Campos, São José dos Campos. São Paulo, Brazil.

A 72-year-old woman with hypertension, diabetes mellitus, hypothyroidism, dyslipidemia, and a single kidney presented with a painful ulcer on the dorsum of her right hand, with a 5-month evolution (Fig. 1). Skin biopsy revealed a chronic inflammatory infiltrate and structures suggestive of Leishmania (Fig. 2). Polymerase chain reaction was positive for leishmaniasis. Intravenous liposomal amphotericin B was initiated, with the dose adjusted to renal function, showing significant clinical improvement. However, 3 months after discharge, a local recurrence occurred. Treatment was then performed with intralesional infiltration of meglumine antimoniate (Glucantime®) – 2 mL per session (4 sessions). The lesion was divided into eight quadrants, with 0.25 mL injected per quadrant, resulting in complete remission (Fig. 3). The patient remains clinically cured after 4 years and continues outpatient follow-up.

American cutaneous leishmaniasis (ACL) is a neglected infectious disease with worldwide distribution, caused by protozoa of the genus *Leishmania* and transmitted by phlebotomine sandflies¹⁻³. In Brazil, it remains a public health concern, particularly in socioeconomically vulnerable regions. Treatment of ACL is challenging due to the toxicity of available drugs and the possibility of relapse¹. This case highlights the therapeutic complexity of ACL in patients with multiple comorbidities. Liposomal



Figure 1. American cutaneous leishmaniasis - initial lesion.

***Correspondence:**

Flávia R. Ferreira
E-mail: dermagica@uol.com.br
2795-501X / © 2025 Portuguese Society of Dermatology and Venereology. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Received: 30-07-2025

Accepted: 06-08-2025

DOI: 10.24875/PJDV.25000051

Available online: 02-09-2025

Port J Dermatol and Venereol. (ahead of print)

www.portuguesejournalofdermatology.com




Figure 2. Histopathology – chronic inflammatory infiltrate and structures suggestive of leishmania. **A:** hematoxylin and eosin. **B:** giemsa, $\times 400$.



Figure 3. Treatment with intralesional antimonials. **A:** demarcation of the areas to be injected, **B:** intraoperative. **C:** final result (6 months).

amphotericin B proved effective, although dosage adjustments were required. The relapse was successfully managed with intralesional antimoniate, supporting its use as a safe and effective alternative to minimize systemic toxicity⁴. In conclusion, an individualized approach and rational use of available therapies, combined with continuous clinical monitoring, are crucial for therapeutic success, especially in patients at increased risk of complications.

Funding

No funding was received for this study.

Conflicts of interest

There are no conflicts of interest to disclose.

Ethical Disclosures

Protection of humans and animals. The authors declare that no experiments involving humans or animals were conducted for this research.

Confidentiality, informed consent, and ethical approval. The authors have followed their institution's confidentiality protocols, obtained informed consent from patients, and received approval from the Ethics Committee. The SAGER guidelines were followed according to the nature of the study.

Declaration on the use of artificial intelligence. The authors declare that no generative artificial intelligence was used in the writing of this manuscript.

References

1. Lima EB, Motta JO, Porto C, Sampaio RN. Tratamento da leishmaniose tegumentar Americana. *An Bras Dermatol.* 2007;82:111-24.
2. Maia-Elkhoury AN, Lima DM, Salomón OD, Buzanovsky LP, Saboyá-Díaz MI, Valadas SY, et al. Interacción entre los determinantes medioambientales y socioeconómicos para el riesgo para leishmaniasis cutánea em América Latina. *Rev Panam Salud Publica.* 2021;45:e49.
3. Navarrete-Dechent C, Cevallos C, Jercic MI, Saudias-Fuentes C, González S, Labarca J. Leishmaniasis cutánea causada por leishmania braziliensis y uso de anfotericina B liposomal. Comunicación de un caso clínico importado. *Rev Chil Infectol.* 2018;35:612-6.
4. Silva RE, Toledo Júnior A, Senna MC, Rabello A, Cota G. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. *Mem Inst Oswaldo Cruz.* 2016;111:512-6.